Boston Pharma Appoints Santiago Arroyo, M.D., Ph.D., As Chief Medical Officer And Constantine Chinoporos, As Chief Business Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals, a new fully integrated drug development company offering an innovative alternative model for drug development commercializiation, today announced the appointment of Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer and Constantine Chinoporos, as Chief Business Officer. Both will work with senior leadership at the company to identify and partner with academic, biotechnology and biopharmaceutical groups to acquire clinical assets at various stages of their development and bring them to market.

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.